Literature DB >> 23454488

Compound heterozygosity of two functional null mutations in the ALPL gene associated with deleterious neurological outcome in an infant with hypophosphatasia.

C Hofmann1, J Liese, T Schwarz, S Kunzmann, J Wirbelauer, J Nowak, J Hamann, H Girschick, S Graser, K Dietz, S Zeck, F Jakob, B Mentrup.   

Abstract

Hypophosphatasia (HPP) is a heterogeneous rare, inherited disorder of bone and mineral metabolism caused by different mutations in the ALPL gene encoding the isoenzyme, tissue-nonspecific alkaline phosphatase (TNAP). Prognosis is very poor in severe perinatal forms with most patients dying from pulmonary complications of their skeletal disease. TNAP deficiency, however, may also result in neurological symptoms such as neonatal seizures. The exact biological role of TNAP in the human brain is still not known and the pathophysiology of neurological symptoms due to TNAP deficiency in HPP is not understood in detail. In this report, we describe the clinical features and functional studies of a patient with severe perinatal HPP which presented with rapidly progressive encephalopathy caused by new compound heterozygous mutations in the ALPL gene which result in a functional ALPL "knock out", demonstrated in vitro. In contrast, an in vitro simulation of the genetic status of his currently asymptomatic parents who are both heterozygous for one mutation, showed a residual in vitro AP activity of above 50%. Interestingly, in our patient, the fatal outcome was due to progressive encephalopathy which was refractory to antiepileptic therapy including pyridoxine, rather than hypomineralization and respiratory insufficiency often seen in HPP patients. The patient's cranial MRI showed progressive cystic degradation of the cortex and peripheral white matter with nearly complete destruction of the cerebrum. To our knowledge, this is the first MRI-based report of a deleterious neurological clinical outcome due to a progressive encephalopathy in an infant harboring a functional human ALPL "knock out". This clinical course of disease suggests that TNAP is involved in development and may be responsible for multiple functions of the human brain. According to our data, a certain amount of residual TNAP activity might be mandatory for normal CNS function in newborns and early childhood.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23454488     DOI: 10.1016/j.bone.2013.02.017

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  12 in total

1.  Clinical utility gene card for: hypophosphatasia - update 2013.

Authors:  Etienne Mornet; Christine Hofmann; Agnès Bloch-Zupan; Hermann Girschick; Martine Le Merrer
Journal:  Eur J Hum Genet       Date:  2013-08-07       Impact factor: 4.246

2.  Genetic analysis of adults heterozygous for ALPL mutations.

Authors:  Agnès Taillandier; Christelle Domingues; Annika Dufour; Françoise Debiais; Pascal Guggenbuhl; Christian Roux; Catherine Cormier; Bernard Cortet; Valérie Porquet-Bordes; Fabienne Coury; David Geneviève; Jean Chiesa; Thierry Colin; Elaine Fletcher; Agnès Guichet; Rose-Marie Javier; Michel Laroche; Michael Laurent; Ekkehart Lausch; Bruno LeHeup; Cédric Lukas; Georg Schwabe; Ineke van der Burgt; Christine Muti; Brigitte Simon-Bouy; Etienne Mornet
Journal:  J Bone Miner Metab       Date:  2017-12-13       Impact factor: 2.626

Review 3.  Hypophosphatasia.

Authors:  Agnès Linglart; Martin Biosse-Duplan
Journal:  Curr Osteoporos Rep       Date:  2016-06       Impact factor: 5.096

Review 4.  Hypophosphatasia: an overview of the disease and its treatment.

Authors:  M L Bianchi
Journal:  Osteoporos Int       Date:  2015-08-06       Impact factor: 4.507

5.  Identification of altered brain metabolites associated with TNAP activity in a mouse model of hypophosphatasia using untargeted NMR-based metabolomics analysis.

Authors:  Thomas Cruz; Marie Gleizes; Stéphane Balayssac; Etienne Mornet; Grégory Marsal; José Luis Millán; Myriam Malet-Martino; Lionel G Nowak; Véronique Gilard; Caroline Fonta
Journal:  J Neurochem       Date:  2017-03       Impact factor: 5.372

Review 6.  The ever-expanding conundrum of primary osteoporosis: aetiopathogenesis, diagnosis, and treatment.

Authors:  Stefano Stagi; Loredana Cavalli; Salvatore Seminara; Maurizio de Martino; Maria Luisa Brandi
Journal:  Ital J Pediatr       Date:  2014-06-07       Impact factor: 2.638

7.  Six ALPL gene variants in five children with hypophosphatasia.

Authors:  Na Su; Min Zhu; Xinran Cheng; Ke Xu; Roland Kocijan; Huijiao Zhang
Journal:  Ann Transl Med       Date:  2021-05

Review 8.  Multiple Functions of MSCA-1/TNAP in Adult Mesenchymal Progenitor/Stromal Cells.

Authors:  David Estève; Jean Galitzky; Anne Bouloumié; Caroline Fonta; René Buchet; David Magne
Journal:  Stem Cells Int       Date:  2015-12-29       Impact factor: 5.443

Review 9.  Neonatal lethal hypophosphatasia: A case report and review of literature.

Authors:  Laura Castells; Pía Cassanello; Felix Muñiz; María-José de Castro; María L Couce
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

10.  Investigation of alpl expression and Tnap-activity in zebrafish implies conserved functions during skeletal and neuronal development.

Authors:  Barbara Ohlebusch; Angela Borst; Daniel Liedtke; Stephanie Graser; Tina Frankenbach; Eva Klopocki; Franz Jakob
Journal:  Sci Rep       Date:  2020-08-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.